Quinazoline inhibitors of egfr tyrosine kinase

A pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a compound of structural Formula I

• or a pharmaceutically acceptable salt thereof, wherein:
• R1-R24 are independently selected from the group consisting of hydrogen and deuterium;
• and
• at least one of R1-R24 is deuterium.

A method of treatment of an EGFR tyrosine kinase-mediated disorder comprising the administration, to a patient in need thereof, of a therapeutically effective amount of a compound of structural Formula I

• or a pharmaceutically acceptable salt thereof, wherein:
• R1-R24 are independently selected from the group consisting of hydrogen and deuterium;
• and
• at least one of R1-R24 is deuterium.

A compound for use as a medicament, having structural Formula I

• or a pharmaceutically acceptable salt thereof, wherein:
• R1-R24 are independently selected from the group consisting of hydrogen and deuterium;
• and
• at least one of R1-R24 is deuterium.

A compound for use in the manufacture of a medicament for the prevention or treatment of a disorder ameliorated by inhibiting EGFR tyrosine kinase activity, said compound having structural Formula I

• or a pharmaceutically acceptable salt thereof, wherein:
• R1-R24 are independently selected from the group consisting of hydrogen and deuterium;
• and
• at least one of R1-R24 is deuterium.

A compound of Formula II:

• or a pharmaceutically acceptable salt thereof, wherein:
• R8-R24 are independently selected from the group consisting of hydrogen and deuterium;
• and
• when R8-R16 are all H, then at least one of R17-R24 is deuterium.